Collegium Pharmaceutical (FRA:354) YoY EBITDA Growth : 14.21% (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Collegium Pharmaceutical YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Collegium Pharmaceutical's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 14.21%.

Collegium Pharmaceutical's EBITDA per Share for the three months ended in Mar. 2025 was €2.27.

Collegium Pharmaceutical YoY EBITDA Growth Historical Data

The historical data trend for Collegium Pharmaceutical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical YoY EBITDA Growth Chart

Collegium Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

1,723.53

-32.39

159.16

39.91

19.32

Collegium Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															73.06	9.70	-12.06	50.80	14.21

Collegium Pharmaceutical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Collegium Pharmaceutical's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(8.073	-	6.766)	/	\| 6.766 \|
=	19.32 %

Collegium Pharmaceutical's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(2.267	-	1.985)	/	\| 1.985 \|
=	14.21 %

Collegium Pharmaceutical YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (FRA:354) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

COLL:USA

Address

100 Technology Center Drive, Stoughton, MA, USA, 02072

Website

https://www.collegiumpharma.com

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Collegium Pharmaceutical Headlines

No Headlines